Under construction – not a live service
Sign in
Taking people in CzechiaPhase 2

Tests PF-08049820 tablets in adults with moderate to severe eczema

Tests a daily tablet against placebo in adults with moderate to severe eczema.

Key facts

Who runs it
Pfizer
Where
Moravska Ostrava A Privoz, Náchod, Pardubice I, and Prague 3, CzechiaSee the 4 sitesAlso in 8 other countries, 49 sites
Registry title
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Status
Recruiting
Phase
Phase 2
People taking part
165 people, planned
Started
20 Nov 2025
Expected to end
2 Feb 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • PF-08049820
  • Placebo
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 64 with moderate to severe atopic dermatitis (eczema) who do not have a suitable prescribed medicine for it.

Age
18 to 64 years
Sex
All sexes can join.
Disease stage
Moderate to severe atopic dermatitis, diagnosed at least 6 months before Day 1 and confirmed by photographs. Affected skin area 10% to 60%, vIGA of 3 or more, EASI of 16 or more, and peak itch score of 4 or more.
Earlier treatment
People who do not have a suitable prescribed medicine for atopic dermatitis.

Main reasons for not taking part

  • An infection that needs treatment
  • Skin conditions other than atopic dermatitis
  • Severe uncontrolled asthma
  • Regular use of a tanning booth or phototherapy for eczema (more than 2 visits per week) within 4 weeks of screening

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participants must meet the following criteria:
  • Are 18 to 64 years of age
  • Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
  • Have moderate to severe AD as defined by the following at screening and baseline visits:; Affected body surface area (BSA) greater than or equal to 10% and up to 60%; Validated Investigator's Global Assessment (vIGA) greater than or equal to 3; Eczema Area and Severity Index (EASI) greater than or equal to 16; AND; -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
  • Do not have a suitable prescribed medicine for AD
  • Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

Who cannot take part

  • Have an infection that requires treatment
  • Have other skin conditions other than AD
  • Participants must not meet the following criteria:
  • Have severe uncontrolled asthma
  • Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Czechia

Also in 8 other countries, 49 sites

  • CCR Ostrava s.r.o.Moravska Ostrava A Privoz, CzechiaTaking people
  • DERMAMEDICA, s.r.o.Náchod, CzechiaTaking people
  • Pratia Pardubice a.s.Pardubice I, CzechiaTaking people
  • Pratia Prague s.r.o.Prague 3, CzechiaTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

Read full original descriptionShow less

The study is seeking participants who:

1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD.

The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

The 4 groups in the trial

  • Arm 2Treatment being tested

    Stages 1 and 2: Tablets taken by mouth daily for 12 weeks

    Treatment: PF-08049820

  • Arm 3Treatment being tested

    Stages 1 and 2: Tablets taken by mouth daily for 12 weeks

    Treatment: PF-08049820

  • Arm 1Treatment being tested

    Stages 1 and 2: Tablets taken by mouth daily for 12 weeks

    Treatment: PF-08049820

  • Arm 4Placebo, for comparison

    Stages 1 and 2: Tablets taken by mouth daily for 12 weeks

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Plain-language title
Tests PF-08049820 tablets in adults with moderate to severe eczemaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07216027, who can take part
Record updated
5 November 2026